Efficacy and safety of DPP-4 inhibitors in diabetic patients undergoing hemodialysis

Efficacy and safety of DPP-4 inhibitors in diabetic patients undergoing hemodialysis - DPP-4 inhibitors in diabetic patients on HD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018445

Enrollment

Registered

2015-07-28

Start date

2015-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes patients with hemodialysis

Interventions

DPP-4 inhibitor, saxagliptin 2.5 mg daily are added on the standard therapy for 24 weeks.Standard therapies are defined as insulin therapy, alpha-glucosidase inhibitors, meglitinides, or diet therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients undergoing hemodialysis more than 6 months, 2)Type 2 diabetes mellitus, 3) Glycated albumin level exceeding 20.0% during 8 consecutive weeks of daily administration of conventional therapy despite dietary therapy or other antidiabetic agents

Exclusion criteria

Exclusion criteria: 1) Infectious disease, 2) Thyroid disease, 3) Malignant tumors, 4) Liver dysfunction, 5) Type 1 diabetes, 6)Treatment with steroids or immunosuppressant, 7) History of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months, 8) Currently hospitalization.

Design outcomes

Primary

Measure	Time frame
Change in glyated albumin level by DPP-4 inhibitors for 24 weeks	—

Secondary

Measure	Time frame
Changes in glyated hemoglobin level and postprandial plasma glucose level by DPP-4 inhibitors, and safety profiles for 24 weeks.	—

Countries

Japan

Contacts

Public ContactMasanori Abe

Nihon University Itabashi Hospital Nephrology, Hypertension and Endocrinology

mabe@med.nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026